All In Biotech

Drug Trial Radar · NCT07361003

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

464

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Jan 2028

Study completion Jul 2028

Sponsor

Sponsor type
Industry
Collaborators
Jiangsu Simcere Biologics Co., Ltd
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal cancer.

Conditions

  • Refractory Metastatic Colorectal Cancer

Interventions

  • Suvemcitug injection, trifluridine/tipiracil tabletsDrug

    Suvemcitug injection at 1.5mg/kg, Trifluridine/tipiracil tablets at 35 mg/m²

  • Suvemcitug placebo injection, trifluridine/tipiracil tabletsDrug

    Suvemcitug placebo injection, Trifluridine/tipiracil tablets at 35 mg/m².

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Phase Ib: Adverse EventsTime frame: From signing informed consent form until 28 days after the last dose of study treatment, up to about 18 months
  3. Phase Ib: ToleranceTime frame: From signing informed consent until 28 days after the last dose of study treatment, for up to 18 months
  4. Phase III: overall survival (OS)Time frame: For about 18 months from the randomization of the last participant

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Harbin Medical University University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.